#Singapore #Philadelphia #biotechnology #Andreas Wallnöfer #Nuevocor

Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board

Nuevocor, an innovative biotechnology firm focused on treating cardiomyopathies with a unique approach to mechanobiology, has exciting news. The company has officially named Dr. Andreas Wallnöfer as its new Chairman of the Board of Directors. This strategic move is expected to enhance Nuevocor's governance and support its ambitious goals in the biotech landscape, especially concerning the treatment of heart conditions.

A Wealth of Experience

Dr. Wallnöfer brings with him an impressive resume, flaunting over 25 years of experience in both the pharmaceutical and biotech sectors. Notably, he served for 12 years within the senior leadership team of F. Hoffmann-La Roche Pharma, gaining in-depth knowledge and insight into drug development and market strategies. His extensive background has also seen him take roles as a board member in several biotechnology firms and as a Partner at prestigious investment firms like BioMedPartners and Jeito Capital.

His investment prowess and operational experience mean that he is highly regarded for successfully guiding many innovative companies towards successful outcomes. Dr. Wallnöfer was also instrumental in facilitating significant transactions, including a recent $3 billion acquisition deal for EyeBio by MSD, a remarkable achievement considering the company’s relative infancy in the marketplace.

Contributions to Cardiovascular Research

Before his venture capital career, Dr. Wallnöfer held a significant position as Head of Cardiovascular and Metabolism Research and Development at Roche. His influential role allowed him to partake in successful product designs and introductions while serving on the Roche/Genentech Portfolio Committee. Renowned for his leadership, he has contributed to the betterment of health through innovative drug developments across various sites worldwide, including Europe, the United States, and Asia.

In addition to this, he took part in the integration of Roche and Genentech's development organizations, a process that streamlined operations and enriched the combined company's product offerings. The experience and prowess he gained during these times are anticipated to be a valuable resource for Nuevocor as it seeks to progress its therapeutic assets.

A Visionary Future

Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor, expressed excitement regarding Dr. Wallnöfer’s joining. He stated, "We are extremely pleased to welcome Andreas as Chairman of Nuevocor's Board and look forward to benefiting from his experience in life-sciences investment as well as expertise in cardiovascular diseases." With Dr. Wallnöfer's significant history of driving companies toward successful exits, it is evident that his involvement will contribute positively in assisting Nuevocor's pursuit of breakthroughs within the biotechnology field.

Dr. Wallnöfer, enthused about his new role, commented, "Nuevocor is at the frontier of next-generation gene therapy. It is very motivating to see how Nuevocor's promising technology may sustainably benefit and improve the lives of patients with cardiomyopathies." This indication of passion reflects the monumental potential he sees in Nuevocor’s mission and technological strategies.

About Nuevocor

Founded with a commitment to revolutionizing the treatment methods for cardiomyopathies, Nuevocor is pioneering an innovative and pathway-centric approach that seeks to address the underlying biomechanical causes of these diseases. With the utilization of its PrOSIA™ mechanobiology platform, Nuevocor aims to reshape how cardiomyopathies are treated, focusing not just on individual genetic deficiencies but on shared disease pathways affecting diverse populations. This approach holds the promise of impacting a broader range of patients, thus aligning with their vision to create functional cures and significantly enhance patient outcomes.